
A panelist emphasizes that shared decision-making in anaphylaxis management is essential, combining evidence-based guidelines with individual patient circumstances and preferences—especially regarding newer options like intranasal epinephrine—to ensure timely, confident use while addressing practical concerns, such as access, cost, and education.



